{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-042317","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.387469+00:00","generated_at":"2026-05-24T10:21:13.971160+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ARS Pharma Q4 net income $49.9M, neffy sales $6.7M; pediatric approval expands market","bullets":["neffy net product revenue $7.3M for FY2024 since Sep launch; Q4 net product revenue $6.7M.","FDA approved neffy 1 mg for children 4+ and 15-30 kg on Mar 5, 2025; in pharmacies May 2025.","Cash, equivalents & short-term investments $314M; operating runway at least 3 years.","Payer coverage: >60% commercial lives under contract by end Q1 2025; >80% by early Q3.","Phase 2b trial for chronic urticaria planned Q2 2025; topline data early 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-042317","json":"https://secwatch.observer/filing/0000950170-25-042317.json","markdown":"https://secwatch.observer/filing/0000950170-25-042317.md","text":"https://secwatch.observer/filing/0000950170-25-042317.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000095017025042317/0000950170-25-042317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000095017025042317/spry-20250320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T10:21:13.971160+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}